Whitepaper: In search of a disease-modifying agent for Parkinson’s disease: a discovery story

Posted: 21 November 2017 | | No comments yet

Are selective, brain-penetrant inhibitors of LRRK2 an answer?

Parkinson’s disease afflicts an estimated 6.3 million people globally, and there is currently no disease-modifying therapy that halts the progression of the disease.

Genentech partnered with Charles River Laboratories to research the possibility of using leucine-rich repeat kinase 2 (LRRK2) inhibitors as therapeutic agents for the treatment of autosomal-dominant Parkinson’s disease.

This report summarises the exhaustive research process used to identify, optimise and test the safety of a compound that showed promise in inhibiting phosphorylated LRRK2 in the brain.

This whitepaper is restricted - login or subscribe free to access

DTR Issue 3 Mini MagThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here